Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest TITUSVILLE Stories

2013-11-25 04:21:07

OLYSIO(TM) is the first once-daily protease inhibitor approved for the treatment of chronic hepatitis C in a combination antiviral regimen for adults with compensated liver disease TITUSVILLE, N.J., Nov. 25, 2013 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen), announced today the U.S. Food and Drug Administration (FDA) has approved OLYSIO((TM)) (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an...

2013-11-22 20:22:56

OLYSIO(TM) is the first once-daily protease inhibitor approved for the treatment of chronic hepatitis C in a combination antiviral regimen for adults with compensated liver disease TITUSVILLE, N.J., Nov. 22, 2013 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen), announced today the U.S. Food and Drug Administration (FDA) has approved OLYSIO((TM)) (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an...

2013-07-29 16:26:16

TITUSVILLE, Fla., July 29, 2013 /PRNewswire/ -- A comparison of nearly 3,000 hospitals throughout Florida and across the U.S. by the Centers for Medicare and Medicaid Services (CMS) shows Parrish Medical Center (PMC) is Central Florida's No. 1 hospital for clinical care, a patient's hospital experience, and low cost. PMC also ranked as the No. 5 independent public hospital in the U.S. and in the top six percent of the 2,985 hospitals analyzed by CMS. This hospital compare data is...

2013-07-16 08:30:24

TITUSVILLE, N.J., July 16, 2013 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen) announced today the recipient of the second scholarship the company is supporting through the Point Foundation, the nation's largest scholarship-granting organization for lesbian, gay, bisexual and transgender (LGBT) students of merit. Janssen is the first pharmaceutical company to fund a Point Scholarship. The Point Scholarship supported by Janssen is for LGBT students...

2013-07-12 23:27:44

Matthew Rand, DMD, MD, PA, specializes in correcting problems with the teeth, gums, jaw and face, including problems caused by birth defects, impacted wisdom teeth and missing teeth. Melbourne, FL (PRWEB) July 11, 2013 Residents in the Melbourne and Titusville areas who have missing teeth, impacted teeth or facial trauma have a new option for treatment now that Dr. Matthew Rand is joining two Coast Dental offices. Dr. Rand practices a wide scope of procedures such as corrective jaw...

2013-05-30 12:27:02

Most Survey Participants Would Recommend Joining a Study to Others TITUSVILLE, N.J., May 30, 2013 /PRNewswire/ -- A survey of a segment of clinical trial participants from the GRACE (Gender, Race And Clinical Experience) trial, the largest-ever study of treatment-experienced adult women with HIV to examine gender differences in response to HIV therapy, found that after taking part in the study, 96 percent of survey responders would recommend participation in a clinical trial to...

2012-12-31 08:21:49

TITUSVILLE, N.J., Dec. 31, 2012 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to SIRTURO(TM) (bedaquiline) Tablets for the treatment of pulmonary multi-drug resistant tuberculosis (MDR-TB) as part of combination therapy in adults. The accelerated approval is based on the surrogate endpoint of time to sputum culture conversion. "SIRTURO(TM) was first discovered in our...

2012-12-10 16:24:00

TITUSVILLE, N.J., Dec. 10, 2012 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT(®) (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT(®) for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults....

2012-11-09 16:24:26

TITUSVILLE, N.J., Nov. 9, 2012 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration (FDA) has approved a new 800mg tablet of PREZISTA(®) (darunavir) for once daily oral administration for the treatment of human immunodeficiency virus (HIV-1) in treatment-naive and treatment-experienced adult patients with no darunavir resistance-associated mutations. PREZISTA(®) is always taken with and at the same time as...

2012-05-29 02:27:29

TITUSVILLE, N.J., May 29, 2012 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration (FDA) has issued a Complete Response letter for a Supplemental New Drug Application (sNDA) for an 800mg tablet of PREZISTA® (darunavir). PREZISTA is approved for once-daily oral administration of 800mg -- two 400mg tablets -- for the treatment of human immunodeficiency virus (HIV-1) in treatment-naive and treatment-experienced adult...